MA
BCRX icon

MUFG Americas’s BioCryst Pharmaceuticals BCRX Stock Holding History

MUFG Americas’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-275
Closed -$3K – 1064
2015
Q3 		$3K Buy
+275
New +$3.67K ﹤0.01% 1037

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MUFG Americas's BCRX Position: Q4 2015 in Review

MUFG Americas sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 275 shares — an estimated $3K sold.

MUFG Americas first reported a position in BCRX in Q3 2015 and held it in 1 quarter. The position peaked at $3K in Q3 2015. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

  • MUFG Americas reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • MUFG Americas sold 275 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $3K.
  • MUFG Americas first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • MUFG Americas's BioCryst Pharmaceuticals position peaked at $3K in Q3 2015.
  • 118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on MUFG Americas's 13F filing for Q4 2015, filed 10 Feb 2016.